![Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers | British Journal of Cancer Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-018-0068-z/MediaObjects/41416_2018_68_Fig1_HTML.png)
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers | British Journal of Cancer
![Nab-Paclitaxel: A Novel Formulation of Taxane for Treatment of Breast Cancer - Prakash Vishnu, Vivek Roy, 2010 Nab-Paclitaxel: A Novel Formulation of Taxane for Treatment of Breast Cancer - Prakash Vishnu, Vivek Roy, 2010](https://journals.sagepub.com/cms/10.2217/WHE.10.42/asset/images/large/10.2217_whe.10.42-fig3.jpeg)
Nab-Paclitaxel: A Novel Formulation of Taxane for Treatment of Breast Cancer - Prakash Vishnu, Vivek Roy, 2010
ecancermedicalscience - FDA approves #atezolizumab with nab-paclitaxel and carboplatin for metastatic #NSCLC without EGFR/ALK aberrations. Read more here: http://bit.ly/33PZaec #Immunotherapy #Oncology #IMpower130 | Facebook
![Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial - The Lancet Oncology Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/5ae6e498-dafa-44cf-bfee-e3287dd90215/gr1.gif)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial - The Lancet Oncology
![Frontiers | Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study Frontiers | Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study](https://www.frontiersin.org/files/MyHome%20Article%20Library/1142256/1142256_Thumb_400.jpg)
Frontiers | Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
![Biomolecules | Free Full-Text | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges Biomolecules | Free Full-Text | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges](https://pub.mdpi-res.com/biomolecules/biomolecules-12-00784/article_deploy/html/images/biomolecules-12-00784-g001.png?1655341055)
Biomolecules | Free Full-Text | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
![The Results of Phase II Clinical Study of KN046 in Combination with Nab- paclitaxel in TNBC were Published in Nature Communications The Results of Phase II Clinical Study of KN046 in Combination with Nab- paclitaxel in TNBC were Published in Nature Communications](https://mma.prnewswire.com/media/2334878/image_1.jpg?p=facebook)
The Results of Phase II Clinical Study of KN046 in Combination with Nab- paclitaxel in TNBC were Published in Nature Communications
![Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System - Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System - Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna](https://journals.sagepub.com/cms/10.1177/2050312119836011/asset/images/large/10.1177_2050312119836011-fig1.jpeg)
Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System - Misa Naganuma, Kohei Tahara, Shiori Hasegawa, Akiho Fukuda, Sayaka Sasaoka, Haruna
![Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety](https://pub.mdpi-res.com/biomedicines/biomedicines-11-02000/article_deploy/html/images/biomedicines-11-02000-g002.png?1689406835)
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer | Molecular Pharmaceutics
![Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial - eBioMedicine Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial - eBioMedicine](https://www.thelancet.com/cms/attachment/b062e329-a90d-44f2-9dc5-939466c9ac94/gr1.jpg)
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial - eBioMedicine
![Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety](https://www.mdpi.com/biomedicines/biomedicines-11-02000/article_deploy/html/images/biomedicines-11-02000-g003-550.jpg)
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
![Sun BioPharma's pancreatic cancer therapy gets US FDA's fast-track status | S&P Global Market Intelligence Sun BioPharma's pancreatic cancer therapy gets US FDA's fast-track status | S&P Global Market Intelligence](https://www.snl.com/articles/404502795.png)
Sun BioPharma's pancreatic cancer therapy gets US FDA's fast-track status | S&P Global Market Intelligence
![Pharmaceutics | Free Full-Text | Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs Pharmaceutics | Free Full-Text | Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-14-01722/article_deploy/html/images/pharmaceutics-14-01722-g001.png?1660810607)